Stellus Cap Investment Azioni (NYSE: SCM)

Stellus Cap Investment (NYSE:SCM) Azioni

Stellus Cap Investment

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Stellus Capital Investment Corporation Common Stock

Stellus Capital Investment Corp

Schwab Strategic Trust Schwab Municipal Bond ETF

Scout Minerals Corp

SILVER CITY MINERALS LTD by SILVER CITY MINERALS LTD

Swisscom AG

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.38 by 2.63 percent. This is a 15.91 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $24.95 million which missed the analyst consensus estimate of $26.62 million by 6.28 percent. This is a 4.02 percent decrease over sales of $26.00 million the same period last year.

Earnings

Earnings Misses

News

Stellus Cap Investment Q1 Adj. EPS $0.37 Misses $0.38 Estimate, Sales $24.95M Miss $26.62M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Stellus Cap Investment to report an earnings per share (EPS) of $0.38.
Anticipation surrounds Stellus Cap Investment's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 8.6% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.39</td>
<td>0.46</td>
<td>0.45</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.40</td>
<td>0.50</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746817341_0.png" alt="eps graph" />
<h3>Performance of Stellus Cap Investment Shares</h3>
Shares of Stellus Cap Investment were trading at $13.07 as of May 08. Over the last 52-week period, shares are down 7.58%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment Earnings Preview

Keefe, Bruyette &amp; Woods analyst Ryan Lynch maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Market Perform and lowers the price target from $13.5 to $13.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on Stellus Cap Investment, Lowers Price Target to $13

Reported Earlier, Stellus Capital Prices $75M Public Offering Of 7.25% Notes Maturing In 2030

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

AVAV

CDXC

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.46 by 13.04 percent. The company reported quarterly sales of $26.498 million which missed the analyst consensus estimate of $27.355 million by 3.13 percent. This is a 2.46 percent decrease over sales of $27.165 million the same period last year.

Stellus Cap Investment Q3 2024 Adj. EPS $0.40 Misses $0.46 Estimate, Sales $26.498M Miss $27.355M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.45 by 11.11 percent. This is a 1.96 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $26.626 million which missed the analyst consensus estimate of $27.006 million by 1.41 percent. This is a 0.15 percent increase over sales of $26.585 million the same period last year.

Earnings Beats

Stellus Cap Investment Q2 2024 Adj. EPS $0.50 Beats $0.45 Estimate, Sales $26.626M Miss $27.006M Estimate

Shares of Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million <a href="https://www.benzinga.com/quote/INDV/earnings">share repurchase program</a>.
Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million.
Indivior shares jumped 14.5% to $12.46 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 157.4% to $1.00 in pre-market trading after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 81.2% to $4.44 in pre-market trading after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 51.4% to $0.4576 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 41.5% to $0.2988 in pre-market trading after gaining around 8% on Wednesday.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 20.8% to $60.90 in pre-market trading after the company reported better-than-expected second-quarter EPS results.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares gained 15.9% to $0.2231 in pre-market trading after falling over 12% on Wednesday.</li>
<li>Stellus Capital Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) shares surged 15.6% to $16.41 in pre-market trading.</li>
<li>ELEVAI Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 15.4% to $0.52 in pre-market trading.</li>
<li>Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) shares gained 7.9% to $16.60 in pre-market trading. Ipsen and Day One entered into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares fell 67.7% to $1.33 in pre-market trading. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>IF Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>) shares declined 59.6% to $6.97 in pre-market trading.</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares fell 22% to $67.85 in pre-market trading after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 19.7% to $0.0367 in pre-market trading after jumping over 75% on Wednesday.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 18.7% to $0.36 in pre-market trading after gaining around 19% on Wednesday.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 18.1% to $18.25 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 16.3% to $11.30 in pre-market trading after declining 10% on Wednesday.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.9% to $0.8998 in pre-market trading. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares dipped 13% to $1.67 in pre-market trading after jumping 54% on Wednesday.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 13% to $11.90 in pre-market trading following a second-quarter earnings miss.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39931967/nvidia-mcdonalds-and-2-other-stocks-insiders-are-selling">Nvidia, McDonald&#8217;s And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BBLG

BLMZ

CERO

DAWN

ELAB

HOTH

INDV

IROQ

SLNA

TIVC

TWOU

VKTX

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

B. Riley Securities analyst Bryce Rowe upgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Sell to Neutral and raises the price target from $12.5 to $13.25.

Upgrades

B. Riley Securities Upgrades Stellus Cap Investment to Neutral, Raises Price Target to $13.25

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.45 by 2.22 percent. This is a 2.22 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $25.996 million which missed the analyst consensus estimate of $26.643 million by 2.43 percent. This is a 7.98 percent increase over sales of $24.075 million the same period last year.

Stellus Cap Investment Q1 2024 Adj EPS $0.44 Misses $0.45 Estimate, Sales $25.996M Miss $26.643M Estimate

Oppenheimer analyst Mitchel Penn maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Perform and maintains $14 price target.

Oppenheimer Maintains Perform on Stellus Cap Investment, Maintains $14 Price Target

B. Riley Securities analyst Bryce Rowe reiterates Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Sell and lowers the price target from $13 to $12.5.

Reiteration

B. Riley Securities Reiterates Sell on Stellus Cap Investment, Lowers Price Target to $12.5

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.500 per share which beat the analyst consensus estimate of $0.450 by 11.11 percent. The company reported quarterly sales of $28.023 million which beat the analyst consensus estimate of $27.408 million by 2.24 percent. This is a 19.93 percent increase over sales of $23.367 million the same period last year.

Stellus Cap Investment Q4 2023 Adj EPS $0.500 Beats $0.450 Estimate, Sales $28.023M Beat $27.408M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.45. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 4.75% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709308823_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $12.77 as of February 29. Over the last 52-week period, shares are down 16.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment's Earnings: A Preview

B. Riley Securities analyst Bryce Rowe downgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Neutral to Sell and announces $13 price target.

Downgrades

B. Riley Securities Downgrades Stellus Cap Investment to Sell, Announces $13 Price Target

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.47. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 4.17% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
<td>0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.17%</td>
<td>-1.54%</td>
<td>-0.7%</td>
<td>2.4%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699304510_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $13.29 as of November 03. Over the last 52-week period, shares are down 5.61%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Stellus Cap Investment

<h3>Upgrades</h3>
According to Barrington Research, the prior rating for Anika Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) was changed from Market Perform to Outperform. For the second quarter, Anika Therapeutics had an EPS of $0.06, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $18.21. Anika Therapeutics closed at $18.38 at the end of the last trading period. 
According to B of A Securities, the prior rating for Parsons Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) was changed from Underperform to Buy. Parsons Corp earned $0.63 in the second quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.28 and a 52-week-low of $38.68. Parsons Corp closed at $54.72 at the end of the last trading period. 
Janney Montgomery Scott upgraded the previous rating for Consolidated Water Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) from Neutral to Buy. Consolidated Water Co earned $0.46 in the second quarter, compared to $0.18 in the year-ago quarter. The stock has a 52-week-high of $25.00 and a 52-week-low of $13.39. At the end of the last trading period, Consolidated Water Co closed at $22.63. 
According to Piper Sandler, the prior rating for Coterra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) was changed from Neutral to Overweight. For the second quarter, Coterra Energy had an EPS of $0.39, compared to year-ago quarter EPS of $1.35. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $22.25. Coterra Energy closed at $28.05 at the end of the last trading period. 
Goldman Sachs upgraded the previous rating for Teledyne Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) from Neutral to Buy. Teledyne Technologies earned $4.67 in the second quarter, compared to $4.43 in the year-ago quarter. The current stock performance of Teledyne Technologies shows a 52-week-high of $448.71 and a 52-week-low of $325.68. Moreover, at the end of the last trading period, the closing price was at $383.39. 
According to Goldman Sachs, the prior rating for Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) was changed from Sell to Buy. For the first quarter, Okta had an EPS of $0.22, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $109.34 and a 52-week-low of $44.13. Okta closed at $71.40 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
According to DA Davidson, the prior rating for Xos Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) was changed from Buy to Neutral. Xos earned $0.14 in the second quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Xos shows a 52-week-high of $2.14 and a 52-week-low of $0.21. Moreover, at the end of the last trading period, the closing price was at $0.37. 
According to Jefferies, the prior rating for NeoGames SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) was changed from Buy to Hold. In the second quarter, NeoGames showed an EPS of $0.00, compared to $0.49 from the year-ago quarter. The stock has a 52-week-high of $27.77 and a 52-week-low of $10.85. At the end of the last trading period, NeoGames closed at $27.11. 
According to Argus Research, the prior rating for Boston Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) was changed from Buy to Hold. Boston Props earned $1.86 in the second quarter, compared to $1.94 in the year-ago quarter. The current stock performance of Boston Props shows a 52-week-high of $90.54 and a 52-week-low of $46.18. Moreover, at the end of the last trading period, the closing price was at $68.12. 
According to Seibert Williams, the prior rating for Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) was changed from Buy to Hold. In the second quarter, Range Resources showed an EPS of $0.30, compared to $1.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $36.37 and a 52-week-low of $22.61. Range Resources closed at $32.45 at the end of the last trading period. 
According to Wedbush, the prior rating for Atreca Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) was changed from Outperform to Neutral. For the second quarter, Atreca had an EPS of $0.49, compared to year-ago quarter EPS of $0.72. At the moment, the stock has a 52-week-high of $2.78 and a 52-week-low of $0.50. Atreca closed at $0.56 at the end of the last trading period. 
According to Citigroup, the prior rating for Urban Outfitters Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) was changed from Buy to Neutral. For the first quarter, Urban Outfitters had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $37.81 and a 52-week-low of $18.76. At the end of the last trading period, Urban Outfitters closed at $36.41. 
Oppenheimer downgraded the previous rating for Stellus Capital Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Outperform to Perform. In the second quarter, Stellus Cap Investment showed an EPS of $0.51, compared to $0.29 from the year-ago quarter. The current stock performance of Stellus Cap Investment shows a 52-week-high of $16.08 and a 52-week-low of $11.77. Moreover, at the end of the last trading period, the closing price was at $14.83. 
B of A Securities downgraded the previous rating for W.P. Carey Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) from Neutral to Underperform. In the second quarter, W.P. Carey showed an EPS of $1.36, compared to $1.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $89.39 and a 52-week-low of $65.78. W.P. Carey closed at $66.86 at the end of the last trading period. 
According to B of A Securities, the prior rating for EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) was changed from Buy to Neutral. In the second quarter, EPR Props showed an EPS of $1.28, compared to $1.17 from the year-ago quarter. The current stock performance of EPR Props shows a 52-week-high of $55.90 and a 52-week-low of $33.92. Moreover, at the end of the last trading period, the closing price was at $42.82. 
According to B of A Securities, the prior rating for Keysight Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) was changed from Neutral to Underperform. Keysight Techs earned $2.12 in the second quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Keysight Techs shows a 52-week-high of $189.38 and a 52-week-low of $139.62. Moreover, at the end of the last trading period, the closing price was at $156.54. 
For OpGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>), HC Wainwright &amp; Co. downgraded the previous rating of Buy to Neutral. In the second quarter, OpGen showed an EPS of $0.93, compared to $2.60 from the year-ago quarter. The stock has a 52-week-high of $12.62 and a 52-week-low of $0.24. At the end of the last trading period, OpGen closed at $0.26. 
BMO Capital downgraded the previous rating for Capri Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Outperform to Market Perform. In the first quarter, Capri Holdings showed an EPS of $0.74, compared to $1.50 from the year-ago quarter. The stock has a 52-week-high of $69.25 and a 52-week-low of $34.17. At the end of the last trading period, Capri Holdings closed at $53.14. 
Piper Sandler downgraded the previous rating for Northern Oil &amp; Gas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) from Overweight to Neutral. For the second quarter, Northern Oil &amp; Gas had an EPS of $1.49, compared to year-ago quarter EPS of $1.72. The current stock performance of Northern Oil &amp; Gas shows a 52-week-high of $42.86 and a 52-week-low of $24.22. Moreover, at the end of the last trading period, the closing price was at $42.02. 
Piper Sandler downgraded the previous rating for Berry Corp (bry) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) from Overweight to Neutral. For the second quarter, Berry Corp had an EPS of $0.15, compared to year-ago quarter EPS of $0.65. The current stock performance of Berry Corp shows a 52-week-high of $10.74 and a 52-week-low of $6.23. Moreover, at the end of the last trading period, the closing price was at $8.39. 
For Public Service Enterprise Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), UBS downgraded the previous rating of Buy to Neutral. Public Service Enterprise earned $0.70 in the second quarter, compared to $0.64 in the year-ago quarter. The stock has a 52-week-high of $69.90 and a 52-week-low of $52.53. At the end of the last trading period, Public Service Enterprise closed at $60.87. 
For Braemar Hotels &amp; Resorts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>), B. Riley Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Braemar Hotels &amp; Resorts showed an EPS of $0.20, compared to $0.37 from the year-ago quarter. The current stock performance of Braemar Hotels &amp; Resorts shows a 52-week-high of $5.85 and a 52-week-low of $2.77. Moreover, at the end of the last trading period, the closing price was at $2.91. 
Bernstein downgraded the previous rating for Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Outperform to Market Perform. In the second quarter, Marriott Intl showed an EPS of $2.26, compared to $1.80 from the year-ago quarter. At the moment, the stock has a 52-week-high of $210.98 and a 52-week-low of $135.90. Marriott Intl closed at $208.51 at the end of the last trading period. 
According to Barclays, the prior rating for CF Industries Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) was changed from Overweight to Equal-Weight. For the second quarter, CF Industries Holdings had an EPS of $2.70, compared to year-ago quarter EPS of $6.19. The stock has a 52-week-high of $119.54 and a 52-week-low of $60.08. At the end of the last trading period, CF Industries Holdings closed at $79.49. 
Barclays downgraded the previous rating for The Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) from Equal-Weight to Underweight. Mosaic earned $1.04 in the second quarter, compared to $3.64 in the year-ago quarter. The stock has a 52-week-high of $63.16 and a 52-week-low of $31.44. At the end of the last trading period, Mosaic closed at $41.69. 
According to Barclays, the prior rating for Nutrien Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) was changed from Overweight to Underweight. In the second quarter, Nutrien showed an EPS of $2.53, compared to $5.85 from the year-ago quarter. The current stock performance of Nutrien shows a 52-week-high of $102.70 and a 52-week-low of $52.23. Moreover, at the end of the last trading period, the closing price was at $66.49. 
Jefferies downgraded the previous rating for Chindata Group Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CD#NASDAQ">CD</a>) from Buy to Hold. Chindata Group Holdings earned $0.12 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Chindata Group Holdings shows a 52-week-high of $9.21 and a 52-week-low of $4.86. Moreover, at the end of the last trading period, the closing price was at $8.11. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
Northland Capital Markets initiated coverage on Manitex International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTX#NASDAQ">MNTX</a>) with an Outperform rating. The price target for Manitex International is set to $10.00. For the second quarter, Manitex International had an EPS of $0.08, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $6.26 and a 52-week-low of $3.48. At the end of the last trading period, Manitex International closed at $5.05. 
For PLAYSTUDIOS Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>), BTIG initiated coverage, by setting the current rating at Neutral. For the second quarter, PLAYSTUDIOS had an EPS of $0.01, compared to year-ago quarter EPS of $0.04. At the moment, the stock has a 52-week-high of $5.00 and a 52-week-low of $3.25. PLAYSTUDIOS closed at $3.82 at the end of the last trading period. 
Truist Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Hold rating. The price target for ODDITY Tech is set to $54.00. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
TD Cowen initiated coverage on Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Market Perform rating. In the second quarter, Sana Biotechnology showed an EPS of $0.45, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $8.75 and a 52-week-low of $2.99. At the end of the last trading period, Sana Biotechnology closed at $5.46. 
With a Neutral rating, B of A Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $60.00 for ODDITY Tech. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
Morgan Stanley initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Equal-Weight rating. The price target for ODDITY Tech is set to $57.00. ODDITY Tech earned $0.56 in the second quarter, compared to $0.33 in the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Buy rating, UBS initiated coverage on CymaBay Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAY#NASDAQ">CBAY</a>). The price target seems to have been set at $18.00 for CymaBay Therapeutics. For the second quarter, CymaBay Therapeutics had an EPS of $0.01, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $14.19 and a 52-week-low of $3.15. CymaBay Therapeutics closed at $13.47 at the end of the last trading period. 
With a Buy rating, HSBC initiated coverage on Monster Beverage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>). The price target seems to have been set at $72.00 for Monster Beverage. Monster Beverage earned $0.39 in the second quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Monster Beverage shows a 52-week-high of $60.47 and a 52-week-low of $42.80. Moreover, at the end of the last trading period, the closing price was at $58.18. 
Needham initiated coverage on Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Buy rating. The price target for Agilysys is set to $92.00. Agilysys earned $0.18 in the first quarter, compared to $0.21 in the year-ago quarter. The current stock performance of Agilysys shows a 52-week-high of $88.16 and a 52-week-low of $46.01. Moreover, at the end of the last trading period, the closing price was at $70.08. 
Telsey Advisory Group initiated coverage on Academy Sports and Outdoors Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with an Outperform rating. The price target for Academy Sports is set to $72.00. For the first quarter, Academy Sports had an EPS of $1.30, compared to year-ago quarter EPS of $1.72. The stock has a 52-week-high of $69.02 and a 52-week-low of $40.70. At the end of the last trading period, Academy Sports closed at $55.19. 
Goldman Sachs initiated coverage on Ducommun Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) with a Neutral rating. The price target for Ducommun is set to $52.00. In the second quarter, Ducommun showed an EPS of $0.54, compared to $0.76 from the year-ago quarter. At the moment, the stock has a 52-week-high of $58.28 and a 52-week-low of $39.46. Ducommun closed at $45.76 at the end of the last trading period. 
JMP Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Market Outperform rating. The price target for ODDITY Tech is set to $66.00. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Neutral rating, Goldman Sachs initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $59.00 for ODDITY Tech. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023

Comments

Stellus Cap Investment

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO